nach oben

Erschienen in:

09.01.2019 | Kardiogener Schock | Schwerpunkt

Therapie des kardiogenen Schocks

Eine Erfolgsgeschichte der deutschen Kardiologie

verfasst von: Prof. Dr. med. R. Erbel, M. Buerke, S. Mohr-Kahaly, H. Oelert, R. Uebis

Erschienen in: Herz | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Gegenüber der Situation in den 60er- und 70er-Jahren des vergangenen Jahrhunderts ist das Letalitätsrisiko für Patienten mit Herzinfarkt, insbesondere für solche mit kardiogenem Schock („myocardial infarction with cardiogenic shock“, MICS), deutlich gesunken. Von einem MICS sind etwa 5–10 % der Patienten mit Myokardinfarkt betroffen; ihr Letalitätsrisiko liegt zwischen 30 und 50 %. Die primäre perkutane Koronarintervention mittels Stentimplantation soll so schnell wie möglich durchgeführt werden, um die Letalität auf rund 20 % zu reduzieren. Dieser Beitrag liefert einen Überblick über die derzeit verfügbaren Optionen zur konservativen und zur fibrinolytischen Behandlung des MICS, zur interventionellen Therapie des kardiogenen Schocks in der Zeit der intravenösen und intrakoronaren Infarkttherapie sowie ohne Thrombolyse. Außerdem werden die aktuell einsetzbaren mechanischen Unterstützungssysteme sowie die Möglichkeiten zur Überwachung und zum Monitoring der Patienten vorgestellt.

Hurst W, Logue RB (1974) Cardiogenic shock. In: Hurst JW, Logue RB, Schlant RC, Wenger NK (Hrsg) The Heart, 3. Aufl. McGraw-Hill, New York, S 1038

Meyer J, Erbel R, Rupprecht HJ et al (1981) Relation between admission time, haemodynamic measurements, and prognosis in acute myocardial infarction. Br Heart J 46:647–656PubMedPubMedCentralCrossRef

Nabel EG, Braunwald E (2012) A tale of coronary artery disease and myocardial infarction. N Engl J Med 366:54–63PubMedCrossRef

Hailer B, Naber CK, Koslowski B et al (2008) Herzinfarktverbund Essen: Ergebnisse nach 1 Jahr. Herz 33:153–157PubMedCrossRef

Thiele H, Zeymer U, Neumann FJ et al (2013) Intra-aortic balloon counter-pulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet 382:1638–1645PubMedCrossRef

Hochman JS, Buller CE, Sleeper LA et al (2000) Cardiogenic shock complicating acute myocardial infarction–etiologies, management and outcome: a report from the SHOCK Trial Registry. Should we emergently revascularize occluded coronaries for cardiogenic shock. J Am Coll Cardiol 36:1063–1070PubMedCrossRef

Thiele H, Zeymer U, Neumann FJ et al (2012) Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 367:1287–1296PubMedCrossRef

De Backer D, Biston P, Devriendt J et al (2010) Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 362:779–789PubMedCrossRef

Ponikowski P, Voors AA, Anker SD et al (2016) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37:2129–2200PubMedCrossRef

10.

Sakr Y, Reinhart K, Vincent JL et al (2006) Does dopamine administration in shock influence outcome? Results of the sepsis occurrence in acutely Ill patients (SOAP) study. Crit Care Med 34:589–597PubMedCrossRef

11.

Boucek RJ, Murphy WP Jr (1960) Segmental perfusion of the coronary arteries with fibrinolysin in man following a myocardial infarction. Am J Cardiol 6:525–533PubMedCrossRef

12.

Amery A, Roeber G, Vermeulen HJ, Verstraete M (1969) Single-blind randomized multicentre trial comparing heparin and streptokinase treatment in recent myocardial infarction. Acta Med Scand Suppl 505:1–35PubMed

13.

Breddin K, Ehrly AM, Fechler L et al (1973) Short-term fibrinolytic treatment in acute myocardial infarction. Dtsch Med Wochenschr 98:861–873PubMedCrossRef

14.

European Cooperative Study Group for Streptokinase Treatment in Acute Myocardial Infarction (1979) Streptokinase in acute myocardial infarction. N Engl J Med 301:797–802CrossRef

15.

Wende W, Stühlen HW, Meyer J et al (1975) Einfluß der Streptokinase induzierten Fibronolyse auf die Ausdehnung des experimentellen Herzinfarktes. Klin Wochenschr 53:755–760PubMedCrossRef

16.

Chazov EI, Matveeva LS, Mazaev AV et al (1976) Intracoronary administration of fibrinolysin in acute myocardial infarct. Ter Arkh 48:8–19PubMed

17.

Rentrop KP, Blanke H, Karsch KR et al (1979) Acute myocardial infarction: intracoronary application of nitroglycerin and streptokinase. Clin Cardiol 2:354–363PubMedCrossRef

18.

Neuhaus KL, Tebbe U, Sauer G et al (1983) High dose intravenous streptokinase in acute myocardial infarction. Clin Cardiol 6:426–434PubMedCrossRef

19.

Schröder R, Neuhaus KL, Leizorovicz A et al (1987) A prospective placebo-controlled double-blind multicenter trial of intravenous streptokinase in acute myocardial infarction (ISAM): long-term mortality and morbidity. J Am Coll Cardiol 9:197–203PubMedCrossRef

20.

Gruppo Italiano per lo Studio della Streptochi-nasi nell’Infarto Miocardico (GISSI) (1987) Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Lancet 2(8564):871–874

21.

Schmidt WG, Merx W, Essen RV et al (1984) Determinants of infarct size in patients successfully treated by intracoronary thrombolysis. Tex Heart Inst J 11:260–267PubMedPubMedCentral

22.

Lambertz H, Schweizer P, Krebs W et al (1984) Echocardiographic monitoring of acute myocardial infarct following intracoronary streptolysis treatment. Z Kardiol 73:321–326PubMed

23.

ISIS-2 (Second International Study of Infarct Survival) Collaborative Group (1988) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 332:349–360CrossRef

24.

Tardiff BE, Califf RM, Morris D et al (1997) Coronary revascularization surgery after myocardial infarction: impact of bypass surgery on survival after thrombolysis. GUSTO investigators. Global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries. J Am Coll Cardiol 29:240–249PubMedCrossRef

25.

Labinaz M, Sketch MH Jr, Stebbins AL et al (1996) Thrombolytic therapy for patients with prior percutaneous transluminal coronary angioplasty and subsequent acute myocardial infarction. GUSTO-I investigators. Global utilization of streptokinase and t‑PA for occluded coronary arteries. Am J Cardiol 78:1338–1344PubMedCrossRef

26.

Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (1990) GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 336(8707):65–71

27.

Holmes DR Jr, Bates ER, Kleiman NS et al (1995) Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries. J Am Coll Cardiol 26:668–674PubMedCrossRef

28.

Ibanez B, James S, Agewall S et al (2018) 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 39:119–177PubMedCrossRef

29.

Rentrop P, De Vivie ER, Karsch KR, Kreuzer H (1979) Acute coronary occlusion with impending infarction as an angiographic complication relieved by a guide-wire recanalization. Clin Cardiol 1:101–106CrossRef

30.

Rutsch W, Schartl M, Mathey D et al (1981) Percutaneous transluminal coronary recanalization: procedure, results, and acute complications. Am Heart J 102:1178–1181PubMedCrossRef

31.

Mathey D, Kuck KH, Remmecke J et al (1980) Transluminal recanalization of coronary artery thrombosis: a preliminary report of its application in cardiogenic shock. Eur Heart J 1:207–212PubMedCrossRef

32.

Meyer J, Schmitz H, Erbel R et al (1981) Treatment of unstable angina pectoris with percutaneous transluminal coronary angioplasty (PTCA). Cathet Cardiovasc Diagn 7:361–371PubMedCrossRef

33.

Meyer J, Schmitz HJ, Kiesslich T et al (1983) Percutaneous transluminal coronary angioplasty in patients with stable and unstable angina pectoris: analysis of early and late results. Am Heart J 106:973–980PubMedCrossRef

34.

Meyer J, Merx W, Schmitz H et al (1982) Percutaneous transluminal coronary angioplasty immediately after intracoronary streptolysis of transmural myocardial infarction. Circulation 66:905–913PubMedCrossRef

35.

Meyer J, Merx W, Dörr R et al (1982) Successful treatment of acute myocardial infarction shock by combined percutaneous transluminal coronary recanalization (PTCR) and percutaneous transluminal coronary angioplasty (PTCA). Am Heart J 103:132–134PubMedCrossRef

36.

Lee L, Erbel R, Brown TM et al (1991) Multicenter registry of angioplasty therapy of cardiogenic shock: initial and long-term survival. J Am Coll Cardiol 17:599–603PubMedCrossRef

37.

Görge G, Haude M, von Birgelen C et al (1995) Reperfusionstherapie bei akutem Myokardinfarkt. Dtsch Med Wochenschr 120:375–382PubMedCrossRef

38.

Erbel R, Meinertz T, Wessler I et al (1984) Recanalization of occluded left main coronary artery in unstable angina pectoris. Am J Cardiol 53:1725–1727PubMedCrossRef

39.

Spiecker M, Erbel R, Rupprecht HJ, Meyer J (1994) Emergency angioplasty of totally occluded left main coronary artery in acute myocardial infarction and unstable angina pectoris—institutional experience and literature review. Eur Heart J 15:602–607PubMedCrossRef

40.

O’Neill WW, Weintraub R, Grines C et al (1992) A prospective, placebo-controlled, randomized trial of intravenous streptokinase and angioplasty versus lone angioplasty therapy of acute myocardial infarction. Circulation 86:1710–1717PubMedCrossRef

41.

O’Neill WW (1992) Angioplasty therapy of cardiogenic shock: are randomized trials necessary? J Am Coll Cardiol 19:915–917PubMedCrossRef

42.

Stone GW, Brodie BR, Griffin JJ et al (1998) Prospective, multicenter study of the safety and feasibility of primary stenting in acute myocardial infarction: in-hospital and 30-day results of the PAMI stent pilot trial. Primary Angioplasty in Myocardial Infarction Stent Pilot Trial Investigators. J Am Coll Cardiol 31:23–30PubMedCrossRef

43.

Mattos LA, Grines CL, Cox D et al (2000) A comparative analysis of primary stenting and optimal balloon coronary angioplasty in acute myocardial infarction. Six month results from the STENT PAMI trial. Arq Bras Cardiol 75:499–514PubMedCrossRef

44.

Saito S, Hosokawa G, Tanaka S, Nakamura S (1999) Primary stent implantation is superior to balloon angioplasty in acute myocardial infarction: final results of the primary angioplasty versus stent implantation in acute myocardial infarction (PASTA) trial. PASTA Trial Investigators. Catheter Cardiovasc Interv 48:262–268PubMedCrossRef

45.

Di Lorenzo E, Sauro R, Varricchio A et al (2009) Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: four year results of the PaclitAxel or sirolimus-eluting stent vs bare metal stent in primary angiOplasty (PASEO) randomized trial. Am Heart J 158:e43–e50PubMedCrossRef

46.

Webb JG, Carere RG, Hilton JD et al (1997) Usefulness of coronary stenting for cardiogenic shock. Am J Cardiol 79:81–84PubMedCrossRef

47.

Dauerman HL, Goldberg RJ, White K et al (2002) Revascularization, stenting, and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. Am J Cardiol 90:838–842PubMedCrossRef

48.

Hochman JS, Sleeper LA, White HD et al (2001) One-year survival following early revascularization for cardiogenic shock. JAMA 285:190–192PubMedCrossRef

49.

Hochman JS, Sleeper LA, Webb JG et al (2006) Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA 295:2511–2515PubMedPubMedCentralCrossRef

50.

Bangalore S, Gupta N, Guo Y et al (2015) Outcomes with invasive vs. conservative management of cardiogenic shock complicating acute myocardial infarction. Am J Med 128:601–608PubMedCrossRef

51.

Jeger RV, Radovanovic D, Hunziker PR et al (2008) Ten-year trends in the incidence and treatment of cardiogenic shock. Ann Intern Med 149:618–626PubMedCrossRef

52.

Redfors B, Angerås O, Råmunddal T et al (2015) 17-year trends in incidence and prognosis of cardiogenic shock in patients with acute myocardial infarction in western Sweden. Int J Cardiol 185:256–262PubMedCrossRef

53.

Zeymer U (2017) Inhospital mortality in patients with infarct-related cardiogenic shock undergoing coronary angiography treated with and without acute revascularization therapy. German Society of Cardiolology, Düsseldorf

54.

Babaev A, Frederick PD, Pasta DJ et al (2005) Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA 294:448–454PubMedCrossRef

55.

Chiu FC, Chang SN, Lin JW et al (2009) Coronary artery bypass graft surgery provides better survival in patients with acute coronary syndrome or ST-segment elevation myocardial infarction experiencing cardiogenic shock after percutaneous coronary intervention: a propensity score analysis. J Thorac Cardiovasc Surg 138:1326–1330PubMedCrossRef

56.

Van Diepen S, Katz JN, Albert NM et al (2017) Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. Circulation 136:e232–e268PubMedCrossRef

57.

Mehta RH, Grab JD, O’Brien SM et al (2008) Clinical characteristics and inhospital outcomes of patients with cardiogenic shock undergoing coronary artery bypass surgery: insights from the society of thoracic surgeons national cardiac database. Circulation 117:876–885PubMedCrossRef

58.

Thiele H, Akin I, Sandri M et al (2018) One-year outcomes after PCI strategies in cardiogenic shock. N Engl J Med 379(18):1699–1710PubMedCrossRef

59.

AWMF Leitlinien (2010) Register Nr. 019/013, S3 Infarktbedingter kardiogener Schock – Diagnose, Monitoring und Therapie. AWMF online

60.

Webb JG, Sanborn TA, Sleeper LA et al (2001) Percutaneous coronary intervention for cardiogenic shock in the SHOCK Trial Registry. Am Heart J 141:964–970PubMedCrossRef

61.

Webb JG, Lowe AM, Sanborn TA et al (2003) Percutaneous coronary intervention for cardiogenic shock in the SHOCK trial. J Am Coll Cardiol 42:1380–1386PubMedCrossRef

62.

Bernat I, Abdelaal E, Plourde G et al (2013) Early and late outcomes after primary percutaneous coronary intervention by radial or femoral approach in patients presenting in acute ST-elevation myocardial infarction and cardiogenic shock. Am Heart J 165:338–343PubMedCrossRef

63.

Pancholy SB, Palamaner Subash Shantha G, Romagnoli E et al (2015) Impact of access site choice on outcomes of patients with cardiogenic shock undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Am Heart J 170:353–361PubMedCrossRef

64.

Thiele H, Jobs A, Ouweneel DM et al (2017) Percutaneous short-term active mechanical support devices in cardiogenic shock: a systematic review and collaborative meta-analysis of randomized trials. Eur Heart J 38:3523–3531PubMedCrossRef

65.

Prondzinsky R, Werdan K (2017) Extracorporal life support during cardiac arrest and cardiogenic shock—how good is the evidence really. Ann Transl Med 5:58PubMedPubMedCentralCrossRef

66.

Roffi M, Patrono C, Collet JP et al (2016) 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the managreement of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 37:267–315PubMedCrossRef

67.

den Uil CA, Akin S, Jewbali LS et al (2017) Short-term mechanical circulatory support as a bridge to durable left ventricular assist device implantation in refractory cardiogenic shock: a systematic review and meta-analysis. Eur J Cardiothorac Surg 52:14–25CrossRef

68.

Attaná P, Lazzeri C, Chiostri M et al (2012) Lactate clearance in cardiogenic shock following ST elevation myocardial infarction: a pilot study. Acute Card Care 14:20–26PubMedCrossRef

69.

Slottosch I, Liakopoulos O, Kuhn E et al (2017) Lactate and lactate clearance as valuable tool to evaluate ECMO therapy in cardiogenic shock. J Crit Care 42:35–41PubMedCrossRef

70.

Levy B, Bastien O, Karim B et al (2015) Experts’recommendations for the management of adult patients with cardiogenic shock. Ann Intensive Care 5(1):52 (Erratum in: (2015) Ann Intensive Care 5(1):26)PubMedCrossRef

71.

Russ MA, Prondzinsky R, Carter JM et al (2009) Right ventricular function in myocardial infarction complicated by cardiogenic shock: improvement with Levosimendan. Crit Care Med 37:3017–3023PubMedCrossRef

Titel: Therapie des kardiogenen Schocks
Eine Erfolgsgeschichte der deutschen Kardiologie
verfasst von: Prof. Dr. med. R. Erbel
M. Buerke
S. Mohr-Kahaly
H. Oelert
R. Uebis
Publikationsdatum: 09.01.2019
Verlag: Springer Medizin
Schlagwörter: Kardiogener Schock
Kardiologische Notfallmedizin
Erschienen in: Herz / Ausgabe 1/2019
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-018-4773-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Therapie des kardiogenen Schocks

Eine Erfolgsgeschichte der deutschen Kardiologie

Zusammenfassung

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

pAVK als Prädiktor für Atherosklerose

ST-Hebungsinfarkt: Die relevantesten Punkte aus den Leitlinien

Wie alles begann

Prävention des akuten Koronarsyndroms

Pacemaker reprogramming rarely needed after device replacement

Kardiale Beteiligung bei Tropenerkrankungen

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin